

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance) (revoked)

TITLE IV

THE EUROPEAN MEDICINES AGENCY — RESPONSIBILITIES AND ADMINISTRATIVE STRUCTURE

Chapter 1

Tasks of the Agency

Article 59

.....

Textual Amendments applied to the whole legislation

- F1** Regulation revoked insofar as it applies to medicinal products for veterinary use (31.12.2020) by [The Veterinary Medicines and Animals and Animal Products \(Examination of Residues and Maximum Residue Limits\) \(Amendment etc.\) \(EU Exit\) Regulations 2019 \(S.I. 2019/676\)](#), regs. 1(2)(b), **5**; 2020 c. 1, **Sch. 5 para. 1(1)**
- Regulation revoked insofar as it applies to medicinal products for human use (31.12.2020) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2019 \(S.I. 2019/775\)](#), **Sch. 9 para. 1(h)** (subject to transitional provisions in [S.I. 2012/1916](#), **Sch. 33A**); 2020 c. 1, **Sch. 5 para. 1(1)**

Changes to legislation:

This version of this Regulation was derived from [EUR-Lex](#) on IP completion day (31 December 2020 11:00 p.m.). It has not been amended by the UK since then. Find out more about legislation originating from the EU as published on legislation.gov.uk.